A group of international experts, including hematopathologists, oncologists, and geneticists
were recently summoned (September 2021, Chicago, IL, USA) to update the 2016/17 World …

The discovery of an identical mutation (V617F) of the JAK2 gene in patients with
polycythemia vera, essential thrombocythemia, and myelofibrosis—the principal …

Background Human myeloproliferative disorders form a range of clonal haematological
malignant diseases, the main members of which are polycythaemia vera, essential …

Background The V617F mutation, which causes the substitution of phenylalanine for valine
at position 617 of the Janus kinase (JAK) 2 gene (JAK2), is often present in patients with …

Background We conducted a randomized comparison of hydroxyurea with anagrelide in the
treatment of essential thrombocythemia. Methods A total of 809 patients with essential …

PURPOSE: To assess life expectancy and prognostic factors for survival in patients with
polycythemia vera and essential thrombocythemia. METHODS: The study sample consisted …

Mutations in signaling molecules of the cytokine receptor axis play a central role in
myeloproliferative neoplasm (MPN) pathogenesis. Polycythemia vera is mainly related to …

1Guy's and St Thomas' NHS Foundation Trust, London, 2Russells Hall Hospital, Dudley,
West Midlands, 3Arrowe Park Hospital Arrowe Park Road Upton Wirral, 4Wellcome Trust …

We assessed frequency and predictive factors for major cardiovascular (CV) events in 707
patients with primary myelofibrosis (PMF) followed in 4 European institutions. A total of 236 …

We searched for JAK2 exon 12 mutations in patients with JAK2 (V617F)-negative
myeloproliferative disorders. Seventeen patients with polycythemia vera (PV), including 15 …